• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21352 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Vagus nerve stimulation for drug-resistant epilepsy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium 177 PSMA in patients with prostate cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Neurophysiological facial nerve monitoring during parotid gland surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2022     Agency for Care Effectiveness (ACE) GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Recombinant blood products for prophylaxis and management of haemophilia A and B
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022     Agency for Care Effectiveness (ACE) Acarbose for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022     Agency for Care Effectiveness (ACE) Sodium zirconium cyclosilicate for treating hyperkalaemia
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022     Agency for Care Effectiveness (ACE) Nicotine replacement therapies to aid smoking cessation
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022     Agency for Care Effectiveness (ACE) Magnetic resonance image guided radiation therapy for patients with cancer
2022     Agency for Care Effectiveness (ACE) Cooral System for the prevention of oral mucositis
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Valoctocogene roxaparvovec (haemophilia A) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tonsillectomy or tonsillotomy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic search for registries in the therapeutic indication of acute lymphoblastic leukaemia]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic search for registries in the therapeutic indication haemophilia B (congenital factor IX deficiency)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, fifth line) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (juvenile psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (enthesitis-associated arthritis) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the final study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Third addendum to Commission A20-61]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for heart transplantation]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulmonary thrombectomy using a disc retriever for pulmonary artery embolism]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Preoperative risk factors: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, advanced) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, adjuvant) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Addendum to Commission A22-63]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to Commission A22-66]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olipudase alfa (ASMD) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal carcinoma, combination with ipilimumab) - Addendum to Commission A22-55]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirmatrelvir/ritonavir (COVID-19) - Benefit assessment acc. to § 35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mosunetuzumab (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Melphalan flufenamide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Medical eradication: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycopyrronium (axillary hyperhidrosis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eravacycline (complicated intra-abdominal infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial carcinoma) - Addendum to Commission A22-61]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - 2nd addendum to commission A22-61]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eladocagene Exuparvovec (aromatic L-amino acid decarboxylase deficiency, = 18 months) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (myasthenia gravis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duration of antibiotic therapy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Difelikefalin (pruritus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for fedratinib acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis type 2) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections < 18 years) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid cancer) - Addendum to Commission A22-59]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brexucabtagene autoleucel (acute lymphatic r/r B cell leukemia, from 26 years of age) - Assessment according to §35a SGB V (1), Sentence 11]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Birch bark extract (epidermolysis bullosa) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51]
2022     Health Sciences Institute in Aragon (IACS) [Non-perforating deep sclerectomy (NPDS) in open angle primary glaucoma (POAG)]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of convalescent plasma donor therapy in the treatment of COVID-19]
2022     Health Technology Wales (HTW) Wearable cardioverter-defibrillators for people at risk of cardiac death
2022     Health Technology Wales (HTW) Photobiomodulation for the prevention and treatment of oral mucositis and radiation dermatitis associated with cancer treatment
2022     Health Technology Wales (HTW) Closed loop systems for the management of type 1 diabetes mellitus in adults and children
2022     Health Technology Wales (HTW) Continuous topical oxygen therapy to treat people with chronic non-healing and complex diabetic foot ulcers
2022     Health Technology Wales (HTW) Left atrial appendage occlusion in patients with atrial fibrillation
2022     Malaysian Health Technology Assessment (MaHTAS) Mesenchymal stem cells for retinitis pigmentosa and other degenerative retina disease
2022     Malaysian Health Technology Assessment (MaHTAS) Transcutaneous oxygen pressure monitoring (TcPO2)
2022     Malaysian Health Technology Assessment (MaHTAS) First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022     Gesundheit Osterreich GmbH (GOeG) [Cost effectiveness of communication training for health care professionals]
2022     Malaysian Health Technology Assessment (MaHTAS) Early cancer detection test for lung (EarlyCDT-Lung)
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Perinatal and infant mental health care models and pathways
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022     NIHR Health Services and Delivery Research programme Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature
2022     NIHR Health Technology Assessment programme Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom